LY2811376 is a small molecule inhibitor of the protein kinase B-Raf, which plays a key role in the MAPK/ERK signaling pathway. It was developed by Eli Lilly and Company for the treatment of cancer and has undergone several preclinical and clinical trials.
The chemical name for LY2811376 is 2-[4-(1H-pyrazol-4-yl)phenyl]-3-[[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]quinazolin-4(3H)-one.
The molecular formula of LY2811376 is C31H28F3N7O2.
The formula weight of LY2811376 is 591.61 g/mol.
The CAS number of LY2811376 is 1194044-20-6.
Top ten keywords from Google and Synonyms:
- LY2811376 mechanism of action
- LY2811376 clinical trials
- LY2811376 side effects
- LY2811376 structure
- LY2811376 cancer treatment
- LY2811376 pharmacokinetics
- LY2811376 dose escalation
- LY2811376 chemical synthesis
- LY2811376 drug resistance
- LY2811376 toxicity
- LY2811376 hydrochloride
- Quinazolin-4(3H)-one, 2-[4-(1H-pyrazol-4-yl)phenyl]-3-[[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]-
Health benefits of this product:
LY2811376 has been primarily developed for the treatment of cancer. It is a selective inhibitor of B-Raf, which plays an important role in the MAPK/ERK signaling pathway. This pathway is often dysregulated in cancer cells and contributes to their growth and survival. By inhibiting B-Raf, LY2811376 may help to slow or stop the growth of cancer cells.
Some potential effects of LY2811376 include:
- Inhibition of tumor growth
- Induction of apoptosis (programmed cell death) in cancer cells
- Reduction of cancer cell proliferation
- Suppression of angiogenesis (formation of new blood vessels)
- Enhancement of anticancer immune response
LY2811376 works by inhibiting B-Raf, a protein kinase that plays a key role in the MAPK/ERK signaling pathway. This pathway is often dysregulated in cancer cells, leading to their uncontrolled growth and survival. By inhibiting B-Raf, LY2811376 may help to restore normal cellular signaling and slow or stop the growth of cancer cells.
LY2811376 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with LY2811376.
LY2811376 can cause several side effects in some patients. These can include:
- Elevated liver enzymes
LY2811376 dosing varies depending on the clinical trial or indication. In some trials, LY2811376 was administered orally once daily, while in other trials it was administered twice daily. Doses ranged from 25 mg to 600 mg per day. The optimal dose of LY2811376 has not yet been established and further research is needed to determine the most effective dosing regimen.
LY2811376 is a small molecule inhibitor of B-Raf that has shown potential as a treatment for cancer. By inhibiting B-Raf, LY2811376 may help to slow or stop the growth of cancer cells by restoring normal cellular signaling. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of LY2811376 in treating cancer